Methylphenidate vs Amphetamine/Dextroamphetamine

Both methylphenidate and amphetamine are highly effective treatments for ADHD, with robust evidence from hundreds of randomized controlled trials spanning more than five decades ^[3][7]. The 2018 Cortese et al. network meta-analysis in The Lancet Psychiatry, which analyzed 133 double-blind RCTs involving 10,068 children/adolescents and 8,131 adults, provided the most comprehensive efficacy comparison to date ^[3]. In children and adolescents, amphetamines showed the largest effect size for clinician-rated symptom improvement (standardized mean difference [SMD] -0.98 vs. placebo), while methylphenidate also showed strong efficacy (SMD -0.78). In adults, amphetamines again led (SMD -0.79) compared to methylphenidate (SMD -0.49) ^[3].

Head-to-head trials comparing the two drug classes directly have generally shown comparable response rates, though some suggest a modest amphetamine advantage particularly in adults. A landmark crossover study by Arnold et al. found that about 41% of children responded equally well to either class, 26% responded better to methylphenidate, and 35% responded better to amphetamine ^[7]. This underscores that individual variation matters more than population-level averages when choosing between these medications.

Both drugs are FDA-approved for ADHD in children aged 6 and older and in adults ^[1][2]. Adderall carries an additional FDA approval for narcolepsy ^[2]. Multiple formulations exist for each: immediate-release methylphenidate (Ritalin) lasts 3-4 hours, while extended-release versions (Concerta, Ritalin LA, Focalin XR) provide 8-12 hours of coverage ^[1]. Immediate-release Adderall lasts 4-6 hours, while Adderall XR provides 10-12 hours ^[2].

For treatment-naive patients, many clinicians start with methylphenidate in children based on guideline preferences and a slightly more favorable tolerability profile in pediatric populations, while amphetamines are often preferred as initial treatment in adults given the stronger effect sizes observed in meta-analyses ^[3][6][8].

Both stimulant classes share a common adverse effect profile related to their catecholaminergic mechanism, including decreased appetite, insomnia, weight loss, increased heart rate, elevated blood pressure, dry mouth, headache, and irritability ^[1][2][5]. In the Cortese meta-analysis, amphetamines were associated with higher dropout rates due to adverse events compared to methylphenidate in children, suggesting modestly lower tolerability ^[3].

Appetite suppression and weight loss tend to be more pronounced with amphetamine-based medications due to their additional mechanism of promoting neurotransmitter release ^[2][5]. Studies report anorexia rates of 20-36% with Adderall XR compared to 4-16% with methylphenidate extended-release formulations ^[1][2]. Insomnia is common with both drug classes, affecting 12-27% of patients, and is generally managed by taking the medication early in the day and avoiding late dosing ^[1][2].

Cardiovascular effects warrant monitoring with both stimulants. Average heart rate increases of 3-6 beats per minute and systolic blood pressure increases of 2-4 mmHg are typical ^[1][2][4]. Both drug classes carry FDA warnings about the risk of sudden cardiac death in patients with pre-existing structural cardiac abnormalities, and cardiovascular screening is recommended before initiating treatment ^[1][2][4]. A large retrospective cohort study found no significant increase in serious cardiovascular events in healthy adults taking stimulants, though the absolute risk in patients with pre-existing heart disease remains a concern ^[4].

Both are Schedule II controlled substances with recognized abuse potential. Amphetamines may carry slightly higher abuse liability due to stronger euphoric effects at supratherapeutic doses and a more pronounced mechanism of dopamine release ^[2][5]. Growth suppression in children (average 1-2 cm height deficit over 2-3 years) has been documented with both classes, though long-term studies suggest this effect may attenuate with continued treatment ^[1][2][6]. Rare psychiatric adverse effects including psychosis, mania, and aggressive behavior occur at comparable rates with both drug classes ^[1][2].

Generic immediate-release methylphenidate (Ritalin) is very affordable at approximately $10-$25 per month, and generic mixed amphetamine salts immediate-release (Adderall) is similarly priced at $15-$30 per month ^[10]. Both are widely available and covered by most insurance plans at preferred generic copay tiers.

Extended-release formulations carry higher costs. Generic methylphenidate ER (Concerta) typically ranges from $30-$80 per month, while generic Adderall XR costs $30-$60 per month ^[10]. Brand-name extended-release products can reach $200-$400 or more per month. Newer branded formulations such as Vyvanse (lisdexamfetamine, a prodrug amphetamine), Jornay PM (evening-dosed methylphenidate), and Azstarys (serdexmethylphenidate/dexmethylphenidate) cost $300-$500 per month without insurance.

Insurance coverage for ADHD stimulants has improved significantly, though some plans require prior authorization or step therapy starting with immediate-release generics before covering extended-release formulations. Manufacturer copay cards and patient assistance programs are available for most branded products. The recent generic availability of several extended-release formulations has improved cost access considerably.

Formulation variety and dosing flexibility are key practical considerations in ADHD treatment. Immediate-release methylphenidate lasts only 3-4 hours and typically requires 2-3 doses per day, while immediate-release Adderall lasts 4-6 hours and is usually dosed 1-2 times daily ^[1][2]. For school-age children, the need for midday dosing at school can be stigmatizing and logistically challenging, driving strong preference for extended-release formulations.

Extended-release options have transformed ADHD treatment convenience. Concerta (methylphenidate OROS) uses an osmotic-release mechanism providing 10-12 hours of coverage with once-daily morning dosing ^[1]. Adderall XR uses a bead-based dual-pulse system for 10-12 hours of coverage ^[2]. Both can be taken once in the morning, eliminating school-time doses. Multiple methylphenidate ER products (Concerta, Ritalin LA, Focalin XR, Aptensio XR, Jornay PM) offer different release profiles to match individual needs ^[1][9].

Neither drug class requires routine blood monitoring, though periodic blood pressure and heart rate checks are recommended ^[4]. Both come in multiple formulation types: tablets, capsules (some of which can be opened and sprinkled on food for children who cannot swallow pills), and liquid/chewable forms ^[1][2]. Methylphenidate has a slight edge in formulation diversity, offering transdermal patches (Daytrana) and chewable tablets in addition to oral forms ^[9].

Both methylphenidate and amphetamine-based stimulants are appropriate first-line options for ADHD, and guidelines generally do not recommend one class over the other as a universal first choice ^[6][8]. The decision often comes down to individual factors including age, comorbidities, prior treatment history, and risk considerations.

For children and adolescents diagnosed with ADHD, many clinicians begin with methylphenidate based on its somewhat better tolerability profile in pediatric populations and the wider variety of pediatric-friendly formulations (patches, liquids, chewable tablets) ^[3][6]. The American Academy of Pediatrics guidelines recommend stimulant medication as first-line treatment for ADHD in children aged 6 and older, with either class being acceptable ^[6].

For adults, the evidence slightly favors amphetamine-based medications in terms of efficacy, with larger effect sizes demonstrated in the Cortese meta-analysis ^[3]. However, this population-level finding may not apply to every individual patient. Adults with comorbid anxiety may respond better to methylphenidate, as amphetamines can sometimes exacerbate anxiety symptoms ^[5][8].

If a patient does not respond adequately to one stimulant class after appropriate dose titration (typically over 2-4 weeks), switching to the other class is standard practice and is successful in approximately 25-30% of initial non-responders ^[7]. Patients with a personal or family history of substance abuse may benefit from lisdexamfetamine (Vyvanse), an amphetamine prodrug with lower abuse potential, or from extended-release methylphenidate formulations that are harder to misuse ^[5][9]. Always work with your prescriber — typically a psychiatrist, neurologist, or experienced primary care physician — to determine the optimal medication and formulation for your specific situation.